A synopsis of eukaryotic Nα-terminal acetyltransferases: nomenclature, subunits and substrates
Bogdan Polevoda1, Thomas Arnesen2,3,4 and Fred Sherman*1

Address: 1Department of Biochemistry and Biophysics, University of Rochester Medical Center, Rochester, NY 14642, USA, 2Department of Molecular Biology, University of Bergen, N-5020 Bergen, Norway, 3Department of Surgical Sciences, University of Bergen, N-5020 Bergen, Norway and 4Department of Surgery, Haukeland University Hospital, N-5021 Bergen, Norway
Email: Bogdan Polevoda - Bogdan_Polevoda@urmc.rochester.edu; Thomas Arnesen - Thomas.Arnesen@mbi.uib.no; Fred Sherman* - Fred_Sherman@urmc.rochester.edu
* Corresponding author

Abstract
We have introduced a consistent nomenclature for the various subunits of the NatA-NatE N-terminal acetyltransferases from yeast, humans and other eukaryotes.

Introduction
N-terminal acetylation has been extensively studied in yeast and humans and represents one of the most common protein modifications in eukaryotes, occurring on approximately 57% of yeast proteins and 84% human proteins [1], although it is rare in prokaryotes. Eukaryotic proteins initiate with methionine residues, which are cleaved from nascent chains if the penultimate residue has a radius of gyration of 1.29 Å or less [2]. N-terminal acetylation subsequently occurs on certain of the proteins, either containing or lacking the methionine residue, as depicted in Fig. 1. The salient features of N-terminal acetylation are summarized in Table 1 and Fig. 2. Detailed reviews on the N-terminal acetyltransferases have appeared [3-7], and the N-terminal acetylation status of 742 human and 616 yeast protein N-termini have been compiled [1]. The wide range and diversity of substrates is due in part to the large number of different N-terminal acetylating enzymes, NatA-NatE. The sequence requirements for N-terminal acetylation vary with the N-terminal

![Figure 1](http://www.biomedcentral.com/1753-6561/3/Suppl_6/S2)

**Figure 1**
A summary of the major pathways of N-terminal processing in eukaryotes, showing the four different termini. 1: Uncleaved and unacetylated Met-Xxx- N-termini; 2: Cleaved and unacetylated Xxx-N-termini; 3: Uncleaved and NatB/NatC acetylated Ac-Met-Xxx- N-termini; 4: Cleaved and NatA acetylated Ac-Xxx-N-termini. See Table 1 and Figure 2 for more detail.
Table 1: Revised nomenclature for N-terminal acetyltransferases

<table>
<thead>
<tr>
<th>Type</th>
<th>NatA</th>
<th>NatB</th>
<th>NatC</th>
<th>NatD</th>
<th>NatE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Original</td>
<td>Ard1p</td>
<td>Nat3p</td>
<td>Mak3p</td>
<td>Nat4p</td>
<td>Nat5p</td>
</tr>
<tr>
<td>Auxiliary subunit</td>
<td>Nat1p</td>
<td>Mdm20p</td>
<td>Mak10p</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Revised</td>
<td>Naa10p</td>
<td>Naa20p</td>
<td>Naa30p</td>
<td>Naa40p</td>
<td>Naa50p</td>
</tr>
<tr>
<td>Auxiliary subunit</td>
<td>Naa15p</td>
<td>Naa25p</td>
<td>Naa35p</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- Naa50p is inferred to be an N-terminal acetyltransferase because of its sequence homology to known NATs.
- Acetylation occurs at least partially on all proteins with Met-Glu-, Met-Asp- and Met-Asn- termini, but only on subclasses of proteins with the other termini.
- Naa15p may be an auxiliary subunit of NatE, as well as an auxiliary subunit of NatA.

Nomenclature
During a recent international meeting on N-terminal acetylation, it was pointed out that there is critical need to revise the gene symbols encoding the N-terminal acetyltransferases. The main reason for changing the nomenclature is so that each of the orthologous genes from different species would have the same name. Furthermore, orthologous genes were assigned not only by similarity of their sequences, but also by their action on the same set of proteins. Yeast NatA and human NatA were shown to acetylate the same set of proteins by comparing a normal yeast strain with the mutant *naa10Δ* and *naa15Δ* strains phenotypically complemented by *yNAT1* and *hNAT1*, suggesting that yNatA and hNatA are similar. However, heterologous combinations, *hARD1 yNAT1* and *yARD1 hNAT1*, were not functional in yeast, suggesting significant structural subunit differences between the species.

Figure 2
The major pathways of N-terminal processing in eukaryotes. Two methionine aminopeptidases (MAP), Map1p and Map2p, cleave N-terminal methionine residues that have small side chains (glycine, alanine, serine, cysteine, threonine, proline, and valine), although methionine is retained on some proteins having penultimate residues of valine. Subsequently, NatA, NatB, and NatC acetylate specific sequences as shown in the figure and in Table 1. Acetylation occurs at least partially on all proteins with Met-Glu-, Met-Asp-, and Met-Asn- termini, but only on subclasses of proteins with the other termini. For example, acetylation occurs at least partially on 43% of proteins in yeast and on 96% of proteins in humans with Ala- termini. In addition, Ac-Cys-, Ac-Val-, Ac-Met-Met-, and Ac-Met-Lys- termini occur on some proteins from humans but not from yeast; it is unknown which NATs are responsible for Ac-Cys-, Ac-Met-Met-, and Ac-Met-Lys- acetylations.

Only two amino acid residues, Met-Asn-, Met-Asp-, or Met-Glu-, are required for at least partial N-terminal acetylation by NatB [1,8]. The other hand, 30 to 50 specific amino acids are required for N-terminal acetylation by NatD [9]. Each of the three major N-terminal acetyltransferases, NatA, NatB and NatC, contain a catalytic subunit, and one or two auxiliary subunits (Table 1). The sequence and functions of the yeast and human orthologous subunits are obviously related. A yeast *ard1Δ nat1Δ* strain was phenotypically complemented by *hARD1 hNAT1*, suggesting that yNatA and hNatA are similar. However, heterologous combinations, *hARD1 yNAT1* and *yARD1 hNAT1*, were not functional in yeast, suggesting significant structural subunit differences between the species [1].
The use of the different symbols NAT, ARD, MDM, and MAK is confusing, and does not provide useful information, especially when applied to human NATs. We believe it can be misleading to assign a gene symbol based on one phenotype of a mutant when a large number of proteins are affected, and when the mutant is pleiotropic. Most importantly, different orthologous genes should have different names. The symbols NAT1, NAT2 and NAT3 denote human genes encoding arylamine N-acetyltransferases, which are distinct from N-terminal acetyltransferases [10]. On the other hand, NCBI has designated the human homologue of the yeast NAT genes as follows: yNAT1 designated as hNARG1; yNAT3 designated as hNAT5; and yNAT5 designated as hNAT13. Also, ARD1 is used to describe the ADP-ribosylation factor protein 1 [11].

Therefore, in this paper we have introduced a new nomenclature for protein N-terminal acetyltransferases in eukaryotes (Table 1). It is important to note that NAA (Nα acetyltransferases) is not used to designate any other gene in yeast or higher eukaryotes. We have assigned each of the subunits of the NatA-NatE complexes a Naa symbol, as presented in Table 1. We have also recommended a nomenclature for paralogs of human NatA complexes containing either Naa10p or Naa11p in combination with either Naa15p or Naa16p (Table 2). The revised symbols, along with synonyms from yeast and humans, are presented in Table 3. Clearly, this revised nomenclature will greatly diminish the confusion in describing orthologous subunits from different species.

### Competing interests
The authors declare that they have no competing interests.

### Authors’ contributions
All authors wrote the manuscript and approved the final version.

### Acknowledgements
This work was supported by the Norwegian Health region West (to T.A.), the Norwegian Research Council (to T.A.), and the National Institutes of Health Grant R01 GM12702 (to F.S.).

This article has been published as part of BMC Proceedings Volume 3 Supplement 6, 2009: Proceedings of the 2007 and 2008 Symposia on Protein N-terminal Acetylation. The full contents of the supplement are available online at [http://www.biomedcentral.com/1753-6561/3?issue=S6](http://www.biomedcentral.com/1753-6561/3?issue=S6).

### References


